ErbB-2 receptor: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett mNo edit summary |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[biochemistry]], '''erbB-2''' ('''Human Epidermal growth factor Receptor 2''', '''HER2''', '''HER-2''', '''HER2/neu''') is a [[cell surface receptor]] that is a "[[protein-tyrosine kinase receptor]] that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor ([[epidermal growth factor receptor]]), the [[erbB-3 receptor]] and the erbB-4 receptor. Activation of the [[erbB-2 receptor]] occurs during heterodimer formation with a ligand-bound erbB receptor family members."<ref>{{MeSH}}</ref> | In [[biochemistry]], '''erbB-2''' ('''Human Epidermal growth factor Receptor 2''', '''HER2''', '''HER-2''', '''HER2/neu''') is a [[cell surface receptor]] that is a "[[protein-tyrosine kinase receptor]] that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor ([[epidermal growth factor receptor]]), the [[erbB-3 receptor]] and the erbB-4 receptor. Activation of the [[erbB-2 receptor]] occurs during heterodimer formation with a ligand-bound erbB receptor family members."<ref>{{MeSH}}</ref> | ||
[[Trastuzumab]] is a [[monoclonal antibody]] against the ErbB-2 receptor that lengthens remission time in metastatic [[breast cancer]].<ref name="pmid17611206">{{cite journal| author=Hudis CA| title=Trastuzumab--mechanism of action and use in clinical practice. | journal=N Engl J Med | year= 2007 | volume= 357 | issue= 1 | pages= 39-51 | pmid=17611206 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17611206 | doi=10.1056/NEJMra043186 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 10:31, 23 March 2010
In biochemistry, erbB-2 (Human Epidermal growth factor Receptor 2, HER2, HER-2, HER2/neu) is a cell surface receptor that is a "protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (epidermal growth factor receptor), the erbB-3 receptor and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members."[1]
Trastuzumab is a monoclonal antibody against the ErbB-2 receptor that lengthens remission time in metastatic breast cancer.[2]
References
- ↑ Anonymous (2024), ErbB-2 receptor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Hudis CA (2007). "Trastuzumab--mechanism of action and use in clinical practice.". N Engl J Med 357 (1): 39-51. DOI:10.1056/NEJMra043186. PMID 17611206. Research Blogging.